IKT · Inhibikase Therapeutics, Inc.
$2.49
-0.01 (-0.40%)
At close · Aug 26
Market Cap
$348.84M
Shares
139.54M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Mark Iwicki | Chief Executive Officer and Director | $30,586,007 |
| Chris Cabell | President and Head of Research and Development | $7,475,289 |
| David McIntyre | Chief Financial Officer | $5,519,690 |
| Milton H. Werner | Former President and Chief Executive Officer | $803,063 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Milton H. Werner | Former President and Chief Executive Officer | $7,980,623 |
| Garth Lees-Rolfe | Former Chief Financial Officer | $1,210,184 |
| Joseph Frattaroli | Former Chief Financial Officer | $370,383 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Milton H. Werner | Former President and Chief Executive Officer | $811,429 |
| Joseph Frattaroli | Former Chief Financial Officer | $579,964 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Milton H. Werner | President and Chief Executive Officer | $744,055 |
| Joseph Frattaroli | C.P.A. Former Chief Financial Officer | $574,765 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Milton H. Werner | President and Chief Executive Officer | $610,655 |
| Joseph Frattaroli | C.P.A. Chief Financial Officer | $487,500 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Joseph Frattaroli | C.P.A. Chief Financial Officer | $1,642,220 |
| Milton H. Werner | President and Chief Executive Officer | $960,719 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Milton H. Werner | President and Chief Executive Officer | $384,617 |
| Joseph Frattaroli | C.P.A. Chief Financial Officer | $300,000 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Dennis Berman | Class III director | Appointed | 2026-06-29 |
| Arvind Kush | Class III director | Appointed | 2026-06-29 |
| David McIntyre | Chief Financial Officer, principal financial officer and principal accounting officer | Appointed | 2025-04-14 |
| Garth Lees-Rolfe | Chief Financial Officer, principal financial officer and principal accounting officer | Resigned | 2025-04-14 |
| Vincent Aurentz | Class I director | Appointed | 2025-02-24 |
| Chris Cabell | President and Head of Research and Development | Appointed | 2025-02-24 |
| Mark Iwicki | President, Chief Executive Officer and principal executive officer | Appointed | 2025-02-18 |
| Milton H. Werner | member of the Board of Directors | Resigned | 2025-02-18 |
| Mark Iwicki | Class I director | Appointed | 2025-02-18 |
| Milton H. Werner | President, Chief Executive Officer and principal executive officer | Resigned | 2025-02-18 |
| Gisele Dion | director | Resigned | 2024-10-22 |
| David Canner | Class II director | Appointed | 2024-10-22 |
| Paul Grint | director | Resigned | 2024-10-22 |
| Arvind Kush | Class III director | Appointed | 2024-10-22 |
| Amit Munshi | Class II director | Appointed | 2024-10-22 |
| Roberto Bellini | Class I director | Appointed | 2024-10-22 |
| Roberto Bellini | Independent Chairperson of the Board of Directors | Appointed | 2024-10-10 |
| Arvind Kush | new director | Appointed | 2024-10-10 |
| Roberto Bellini | new director | Appointed | 2024-10-10 |
| Amit Munshi | new director | Appointed | 2024-10-10 |
| David Canner | new director | Appointed | 2024-10-10 |
| Paul Grint | member of the Board of Directors | Resigned | 2024-10-10 |
| Gisele Dion | member of the Board of Directors | Resigned | 2024-10-10 |
| Arvind Kush | Class III director | Appointed | 2024-10-10 |
| David Canner | Class II director | Appointed | 2024-10-10 |
Key facts
CIK
1750149
CUSIP
45719W205
13F (30d)
102 filings
100 filers
Visit website
Investor relations